Zanubrutinib and tafasitamab for mantle cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests two targeted drugs, zanubrutinib and tafasitamab, for people with mantle cell lymphoma. The goal is to see if this combination works better than standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have mantle cell lymphoma confirmed by a biopsy.
- Your cancer is measurable on a PET/CT scan and needs treatment in your doctor's opinion.
- You are able to care for yourself (ECOG performance status 0-2).
- Your blood counts and organ function (kidney, liver) are within certain limits.
- For Phase 1: your lymphoma has come back after 1-3 prior treatments. For Phase 2: you have newly diagnosed lymphoma and are not a candidate for intensive chemo.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of a targeted pill (zanubrutinib) with standard chemotherapy (R-CHOP/R-DHAP) for people newly diagnosed with mantle cell lymphoma. The goal is to see how well this approach works and to potentially improve treatment outcomes for this type of lymphoma.
This trial tests a combination of three targeted drugs for mantle cell lymphoma that has come back or not responded to prior treatment. It aims to see if this new drug cocktail can work better than standard options.
This trial tests a combination of three medications (zanubrutinib, obinutuzumab, and sonrotoclax) for people with mantle cell lymphoma, a type of blood cancer. The goal is to see if this combination is safe and effective, and it may be an option for people who are older or have health issues that make a stem cell transplant too risky.
This trial studies whether combining zanubrutinib and rituximab can better control indolent (slow-growing) mantle cell lymphoma. It aims to improve how long participants can stay without the lymphoma worsening.
This trial tests a combination of three drugs—obinutuzumab, zanubrutinib, and lenalidomide—as a first treatment for mantle cell lymphoma. The goal is to see if this approach is safe and effective for patients who have not had prior therapy.
This trial is testing a medicine called zanubrutinib to see if it can help prevent mantle cell lymphoma from coming back after initial treatment. It is for people who have already finished their first treatment and achieved at least a partial response.
Hear when a new Mantle Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.